Chandra Bhagat Pharma Ltd (542934)
சுருக்கம்
The board meets on 13 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 13 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- H2 FY26
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 13 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Chandra Bhagat Pharma Ltd-இன் இயக்குநர் குழுக் கூட்டம் 13 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, H2 FY26, Chandra Bhagat's revenue was ₹91.0 Cr (+313.6% year on year, +250.0% on the previous half-year), and net profit ₹3.0 Cr; the operating margin was 2.2%.
| H2 FY26 (₹ கோடி) | மதிப்பு | YoY H2 FY25-உடன் | முந்தைய அரையாண்டுடன் ஒப்பீடு |
|---|---|---|---|
| வருவாய் | ₹91.0 | +313.6% | +250.0% |
| செயல்பாட்டு லாபம் | ₹2.0 | — | +0.0% |
| நிகர லாபம் | ₹3.0 | — | — |
| EPS (₹) | 3.45 | — | +475.0% |
| செயல்பாட்டு லாப வரம்பு | 2.2% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Chandra Bhagat Pharma approved the allotment of 66,00,000 convertible warrants on a preferential basis at an issue price of ₹44 each, representing a total consideration of ₹29.04 crore. The company has already received ₹7.26 crore (25% upfront subscription) against this allotment. The warrants are convertible 1:1 into equity shares within 18 months. The total potential capital injection of ₹29.04 crore is significant, representing approximately 83% of the company's current market cap of ₹35 crore and 85% of net worth.
- Allotment of 66,00,000 convertible warrants at ₹44 per warrant
- Upfront consideration of ₹7,26,00,000 (25%) received by the company
- Total transaction value upon full conversion stands at ₹29.04 crore
- Conversion ratio of 1:1 into equity shares exercisable within 18 months
- Allottees include 7 promoter group entities (50 lakh warrants) and 2 non-promoters (16 lakh warrants)
Chandra Bhagat Pharma has received in-principle approval from BSE for the preferential issue of 66,00,000 convertible warrants into equity shares of face value ₹10 each at a minimum price of ₹44 per warrant. The fundraise totals at least ₹29.04 crore, which represents approximately 83% of the company's current market capitalization of ₹35 crore. The warrants are being offered to both promoters and non-promoters, subject to statutory approvals and allotment within regulatory timelines. BSE has mandated strict compliance including undertakings regarding intra-day trading and a 20-day post-allotment listing application window.
- Received BSE in-principle approval for 66,00,000 convertible warrants
- Each warrant convertible into equity shares of face value ₹10 at not less than ₹44 each
- Minimum fundraise size of ₹29.04 crore, representing ~83% of market cap
- Offered on preferential basis to promoter and non-promoter entities
- Company required to apply for final listing within 20 days of allotment
Chandra Bhagat Pharma has issued a corrigendum to its AGM notice scheduled for September 1, 2026, following a request from BSE. The update provides the exact web link to the SEBI ICDR compliance certificate issued by Practicing Company Secretary M/s. Dilip Swarnkar & Associates for the proposed issuance of 66,00,000 convertible warrants on a preferential basis. All other items and contents of the original AGM notice dated August 6, 2026, remain unchanged.
- Issued corrigendum to AGM notice scheduled for September 1, 2026, at 04:00 PM IST
- Updates compliance link for the proposed issuance of 66,00,000 convertible warrants on a preferential basis
- BSE requested exact web link to the SEBI ICDR compliance certificate from M/s. Dilip Swarnkar & Associates
- M/s. Amit Dharmani & Associates appointed as Scrutinizer for the voting process
Chandra Bhagat Pharma has convened its 23rd AGM for September 1, 2026, to approve a major capital restructuring. The company proposes increasing its authorized share capital from ₹8.5 crore to ₹15 crore to facilitate growth. Most significantly, it seeks approval to issue up to 66,00,000 convertible warrants on a preferential basis to both promoters and non-promoters. Given the company's small market capitalization of ₹30 crore, this fundraise is highly material and suggests a significant upcoming capital infusion.
- Proposed issuance of up to 66,00,000 convertible warrants to promoters and non-promoters on a preferential basis
- Increase in Authorized Share Capital by 76.5% from ₹8.5 crore to ₹15 crore
- Reported FY26 export earnings (FOB value) of ₹80.24 crore, up from ₹69.58 crore in FY25
- Promoter holding remains strong at 73.02% as of March 2026
- Annual General Meeting scheduled for September 1, 2026, to vote on these resolutions
Chandra Bhagat Pharma's board has approved a preferential issue of 66 lakh convertible warrants to raise ₹29.04 crore. The issue price of ₹44 per warrant represents a premium of approximately 11.6% over the current market price of ₹39.4. Promoters and promoter group members are the primary subscribers, committing to 50 lakh of the 66 lakh warrants. This fundraise is highly material, representing nearly 97% of the company's current market capitalization of ₹30 crore.
- Total fundraise of ₹29.04 crore through the issuance of 66,00,000 convertible warrants.
- Issue price set at ₹44 per warrant, including a premium of ₹34 per share.
- Promoters and promoter group to subscribe to 50,00,000 warrants, signaling strong internal confidence.
- Authorized share capital increased from ₹8.5 crore to ₹15 crore to facilitate the issuance.
- Warrants are convertible into equity shares at a 1:1 ratio within a period of 18 months.
Chandra Bhagat Pharma has scheduled a board meeting for August 5, 2026, to consider raising funds through a preferential allotment of equity shares or convertible warrants. This move comes as the company maintains a small market capitalization of Rs 26 Cr despite a significant TTM revenue of Rs 204 Cr. The board will also discuss increasing the authorized share capital to facilitate this issuance. The consideration for the issue may be in cash or 'other than cash', which often indicates potential asset acquisitions or debt-to-equity swaps.
- Board meeting scheduled for August 5, 2026, to approve preferential allotment.
- Proposal includes issuance of equity shares, convertible warrants, or other instruments.
- Trading window for insiders closed from July 30, 2026, until 48 hours post-meeting.
- Company currently has a low market cap of Rs 26 Cr relative to TTM revenue of Rs 204 Cr.
- Promoter holding has shown a steady increase from 69.29% in Sep 2024 to 73.02% in Mar 2026.
Chandra Bhagat Pharma has submitted a certificate to the BSE stating that the requirement to file a Corporate Governance Report for the quarter ended June 30, 2026, is not applicable. This exemption is granted under Regulation 15 of SEBI (LODR) Regulations, 2015, primarily because the company is listed on an SME Exchange. While the company's current net worth of ₹34 crore exceeds the ₹25 crore threshold for general exemption, its SME listing status provides the regulatory basis for this non-applicability. This is a standard procedural filing for companies in this category and has no impact on financial operations.
- Exemption claimed under Regulation 15 of SEBI (LODR) Regulations, 2015 for the quarter ended June 30, 2026
- Company qualifies for exemption due to its listing on the SME Exchange
- Current Net Worth of ₹34 crore is above the ₹25 crore general exemption limit, but SME status takes precedence
- Paid-up equity share capital remains below the ₹10 crore threshold mentioned in the regulation
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
